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This study assessed the antiproliferative activity of sapacitabine (CYC682, CS-682) in a panel of 10 human cancer cell lines with
varying degrees of resistance or sensitivity to the commonly used nucleoside analogues ara-C and gemcitabine. Growth inhibition
studies using sapacitabine and CNDAC were performed in the panel of cell lines and compared with both nucleoside analogues and
other anticancer compounds including oxaliplatin, doxorubicin, docetaxel and seliciclib. Sapacitabine displayed antiproliferative activity
across a range of concentrations in a variety of cell lines, including those shown to be resistant to several anticancer drugs.
Sapacitabine is biotransformed by plasma, gut and liver amidases into CNDAC and causes cell cycle arrest predominantly in the G2/M
phase. No clear correlation was observed between sensitivity to sapacitabine and the expression of critical factors involved in
resistance to nucleoside analogues such as deoxycytidine kinase (dCK), human equilibrative nucleoside transporter 1, cytosolic
50-nucleotidase and DNA polymerase-a. However, sapacitabine showed cytotoxic activity against dCK-deficient L1210 cells indicating
that in some cells, a dCK-independent mechanism of action may be involved. In addition, sapacitabine showed a synergistic effect
when combined with gemcitabine and sequence-specific synergy with doxorubicin and oxaliplatin. Sapacitabine is therefore a good
candidate for further evaluation in combination with currently used anticancer agents in tumour types with unmet needs.
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Sapacitabine (Figure 1A; CYC682, Cyclacel Ltd, Dundee, UK;
CS-682, Sankyo, Tokyo, Japan) is a novel 20-deoxycytidine analogue
(1-(2-C-cyano-2-deoxy-b-D-arabino-pentafuranosyl)N4-palmitoyl-
cytosine), which was synthesised by incorporating an additional
N4-palmitoyl group to protect the amino group (Kaneko et al,
1997). The rational of adding a N4-palmitoyl moiety to CNDAC
(1-(2-C-cyano-2-deoxy-b-D-arabino-pentafuranosyl) cytosine) result-
ing in sapacitabine was expected to protect the amino group of
CNDAC, resulting in a better diffusion into gastro-intestinal cells
thereby allowing the oral administration of the drug. Sapacitabine
is primarily metabolised by plasma, gut and liver amidases into the
active metabolite CNDAC, which is subsequently transported
inside cells and then phosphorylated by deoxycytidine kinase
(dCK) into CNDAC triphosphate before being incorporated into
cellular DNA (Figure 1B). Extension during DNA replication leads
to single-strand breaks directly caused by b-elimination (Liu et al,
2005). DNA strand breaks that arise from further processing
initiate signals that activate the G2 checkpoint pathway, ultimately
resulting in cellular apoptosis. After incubation with cytostatic
concentrations of CNDAC, cell cycle arrest in G2 occurs following a
delayed S phase (Liu et al, 2005). This differs from other
deoxycytidine analogues such as ara-C or gemcitabine for which
the predominant biological alterations consist of cell cycle arrest in
S phase (Azuma et al, 2001). Cytotoxic effects of CNDAC have also
been associated with intracellular accumulation of CNDAC
triphosphate and chain termination (Galmarini, 2006).
Although they have a similar mechanism of action, preliminary
in vitro and in vivo investigations have shown that CNDAC and
sapacitabine may display overlapping cytotoxic effects with some
cancer cells being more sensitive to sapacitabine than CNDAC.
Furthermore, data have suggested that the sapacitabine cytotoxi-
city profile may differ from that of other nucleoside analogues
(Kaneko et al, 1997; Faivre et al, 1999; Hanaoka et al, 1999; Zhang
et al, 1999; Wu et al, 2003; Matsuda and Sasaki, 2004). Therefore,
further investigations are required to ascertain the exact mechan-
ism of action of sapacitabine, to evaluate the toxicity of
combinations with other compounds and to screen the range of
its activity in various tumour systems that may eventually lead to
clinical application.
In this study, we tested the antiproliferative activity and cell
cycle effects of sapacitabine against a panel of colon, breast, lung
and ovarian cancer cell lines considered as being representative of
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stumours warranting the development of this novel anticancer
agent. The antiproliferative effects of sapacitabine were observed
in a variety of cell lines resistant to other anticancer drugs. Levels
of mRNA expression of critical factors including various
transporters and enzymes involved in resistance to nucleoside
analogues, such as dCK, human equilibrative nucleoside trans-
porter 1 (hENT1), cytosolic 50-nucleotidase (cN-II) and DNA
polymerase-a (POL), were determined in all cell lines and
correlated with sapacitabine cytotoxicity. Sapacitabine also showed
cytotoxic activity against dCK-deficient L1210 cells.
Considering that this compound may be amenable to clinical
trials in combination with other anticancer agents, combinations
of sapacitabine with several anticancer agents commonly used in
practice, such as gemcitabine, oxaliplatin, doxorubicin, docetaxel
and seliciclib, a novel CDK inhibitor (McClue et al, 2002; Meijer
and Raymond, 2003), were also explored.
MATERIALS AND METHODS
Cell lines
A panel of colon (HT29, HCT116, COLO205, HCC2998), breast
(MCF7, MDA-MB-435), lung (HOP62, HOP92), ovarian (OVCAR3,
IGROV1) cancer cell lines was purchased from the ATCC
(Rockville, MD, USA). Cells were grown as monolayers in RPMI
A
HO
O
O
N
N
O
HO
NC
HO
NH2 NH2 NH2
O
NC
N
N
O
F F
O
HO
N
N
HO
O
H
H
H
H
O
HO 
HO
N
N
HO 
O
B
hENT
dCK
CMPK
CDA
dCTP
NDPK
F
e
e
d
b
a
c
k
 
i
n
h
i
b
i
t
i
o
n
AraCMP 
GemCMP 
CNDACMP
RNR
dCMPDA
Gemcitabine
Ara-C
CNDAC
DNA Apoptosis
Ara-C
CNDAC
Gemcitabine
Ara-U
CNDAC-U
Gem-U
AraCDP 
GemCDP 
CNDACDP
AraUMP 
GemUMP 
CNDACUMP
AraCTP 
GemCTP 
CNDACTP
CH3(CH2)14CNH
Sapacitabine CNDAC Gemcitabine Ara-C
Figure 1 (A) Chemical structure of sapacitabine, CNDAC, gemcitabine and ara-C; (B) Metabolism of ara-C, gemcitabine and CNDAC. Nucleosides
enter the cell via the human equilibrative nucleoside transporter 1 (hENT1). Inside the cell, they are phosphorylated to monophosphates by deoxycytidine
kinase (dCK). Ara-CMP and CNDACMP are subsequently phosphorylated to ara-CTP and CNDACTP, the active metabolites. Incorporation of CTPs into
DNA blocks DNA synthesis and leads to cell death. Ara-CTP formation can be obstructed. Cytidine deaminase (CDA) and deoxycytidylate deaminase
(dCMPD) convert ara-C to ara-Uridine (U), and ara-CMP to ara-UMP, respectively. dCTP can be synthesised directly via the de novo pathway by
ribonucleotide reductase (RNR).
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smedium supplemented with 10% fetal calf serum (Invitrogen,
Cergy-Pontoise, France), 2mM glutamine, 100unitsml
 1 penicillin
and 100mMml
 1 streptomycin.
Cell cytotoxicity assays
All the data generated were the result of three separate experiments
performed in duplicate. Cell viability was determined using the
MTT assay, which was carried out as described previously (Hansen
et al, 1989). Briefly, cells were seeded in 96-well plates at a density
of 2 10
3cells per well. Cells were incubated for 120h and
then 0.4mgml
 1 of MTT dye (3-[4, 5-dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide; Sigma, Saint-Quentin Fallavier,
France) was added for 4h at 371C. The monolayer was suspended
in 0.1ml of DMSO and the absorbance at 560nm was measured
using a microplate reader (Dynatech, Ann Arbor, MI, USA).
Positive and negative controls included wells with untreated cells
or medium containing MTT with no cells, respectively. The
conversion of yellow water-soluble tetrazolium MTT into purple
insoluble formazan is catalysed by mitochondrial dehydrogenases
and is used to estimate the number of viable cells. The control
value corresponding to untreated cells was taken as 100% and the
viability of treated samples was expressed as a percentage of the
control. IC50 values were determined as concentrations that
reduced cell viability by 50%.
For single agent studies, cells were seeded and allowed to settle
for 24h before treatment with increasing concentrations of
sapacitabine, CNDAC, seliciclib (CYC202, R-roscovitine; Meijer
and Raymond, 2003), a novel cyclin dependent kinase inhibitor,
doxorubicin, docetaxel, cisplatin, oxaliplatin, ara-C, 5-FU or
gemcitabine for 48h. After incubation, the cells were allowed to
recover in compound-free medium for 72h, before determination
of growth inhibition using the MTT assay.
For sequential or simultaneous studies, three schedules were
implemented comprising sequential exposure to sapacitabine
(48h) followed by the second agent (24h); sequential exposure
with one anticancer agent (24h) followed by treatment with
sapacitabine (for 48h); and simultaneous exposure to both agents
(48h). In sequential exposure schedules, cells were seeded
and allowed to grow in the presence of various concentrations
of sapacitabine, doxorubicin, docetaxel, seliciclib, oxaliplatin
or gemcitabine for 24 or 48h. The supernatant was then removed
and the second compound was added. After an additional
exposure period, the second compound was removed and
cells were allowed to recover in drug-free medium for 72h.
Growth inhibition was then determined by the MTT assay.
For simultaneous exposure, cells were seeded and treated
after 24h with increasing concentrations of sapacitabine alone
or with seliciclib, doxorubicin, docetaxel, oxaliplatin or gem-
citabine in various concentrations corresponding to the IC20,I C 40,
IC60 and IC80 values. After approximately four doubling times
(120h), the growth inhibitory effects were measured using the
MTT assay.
Statistical analysis and determination of synergistic
activity
Drug combination effects were determined using the Chou and
Talalay method as described elsewhere (Chou and Talalay, 1984)
based on the median effect principle. Combination index (CI)
values of o1 indicate synergy, a value of 1 indicates additive
effects and a value of 41 indicates antagonism. Variability
between experiments led us to consider that CI values ranging
from 0.8 to 1.2 mainly represent additive effects. Thereby
calculation of a CI below 0.8 is an indication of synergy, above
1.2 antagonism and between 0.8 and 1.2 an indication of additive
effects.
Data were analysed using the concentration effect analysis
software (Biosoft, Cambridge, UK). For statistical analysis and
graphs, the Instat and Prism software (GraphPad, San Diego, CA,
USA) were used. Experiments were performed three times, in
duplicate. Means and standard deviations were compared using
Student’s t-test (two-sided P-value).
Cell cycle analysis and apoptosis
The cell cycle stage and percentage of apoptotic cells were assessed
by flow cytometry. In brief, cells were seeded in 25cm
3 flasks and
were untreated or treated with various concentrations of
sapacitabine. At the indicated time points, adherent and non-
adherent cells were collected, washed with PBS, fixed in 70%
ethanol and stored at 41C until use. Cells were re-hydrated in PBS,
incubated for 20min at room temperature (251C) with 250mgml
 1
RNAse A with Triton X-100 and 20min at 41C with 50mgml
 1
propidium iodide in the dark. The cell cycle distribution and
percentage of apoptotic cells were determined with FACScan
flow cytometer and analysed by FACS Calibur (Becton Dickinson,
Le-Ponte-de-Claix, France).
RNA extraction, RT–PCR and quantitative PCR
Expression levels of the various metabolic factors involved in ara-C
resistance were assessed by quantitative real-time RT–PCR
performed in a LightCycler detection system (Roche, Mannheim,
Germany). Briefly, cDNA (5ml) was mixed with primers (300nM
each), LightCycler-FastStart DNA Master SYBR Green I (hENT1
transporter and POL) or LightCycler-FastStart DNA master
hybridisation probes (18S, dCK and cN-II), and probes (130nM;
if necessary) in a total volume of 20ml. These reactions were
prepared in duplicate in three separate experiments. The primer
sequences used were:
hENT1 (FOR: gctgggtctgaccgttgtat; REV: ctgtacagggtgc
atgatgg);
dCK (FOR: aaacctgaacgatggtctttttacc; REV: ctttgagct
tgccattcagaga);
cN-II (FOR: acctgctgtattaccctttcagcta; REV: gctccac
cgttgattcatga);
POL (FOR: agcttgacctgattgctgtc; REV: atgacgggaca
aagacaagg).
The relative amount of each target gene and a reference gene
(18S) were determined for all samples and the calibrator cell line,
HL-60. Ratio results obtained with RelQuant software were
considered as final relative PCR arbitrary units. Results were then
expressed as PCR arbitrary units in all cell lines related to HL-60
cells PCR arbitrary unit expression.
RESULTS
Single agent studies
The antiproliferative effect of sapacitabine was examined in a panel
of 10 cancer cell lines as displayed in Table 1. Time course
experiments showed that optimal antiproliferative effects were
achieved when cells were exposed to sapacitabine for 48h.
Concentrations of sapacitabine required to achieve an IC50 ranged
from 370.6mM for the colon cancer cell line HCT116 to 67714mM
for the breast cancer cell line MDA-MB-435.
The antiproliferative effects of sapacitabine were compared to
those of CNDAC and several commonly used anticancer agents
such as gemcitabine, doxorubicin, docetaxel, oxaliplatin and
seliciclib. Results are shown in Figure 2. Sapacitabine displayed
cytotoxic effects against all cancer cell lines irrespective of the
origin of the tumour and usually at lower concentrations than
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srequired for CNDAC. The cytotoxicity profiles of the other
nucleoside analogues tested including CNDAC and ara-C appeared
to differ from that of sapacitabine suggesting differences in the
metabolism, mechanism of action and/or resistance between
sapacitabine and other cytidine analogues.
Effect of sapacitabine and CNDAC on cell cycle changes
The HCT116 cell line was selected, as the most sensitive model to
both sapacitabine and CNDAC, for further investigation in this study.
Cells were incubated with a concentration of 6mM (twice the IC50)o f
Table 1 Antiproliferative effects (IC50 using MTT assay) of sapacitabine, CNDAC, seliciclib and several anticancer compounds in a panel of human and
murine cancer cell lines
IC50 (lM)
Tumour type Cell line Sapacitabine CNDAC Gemcitabine Ara-C Seliciclib Doxorubicin Docetaxel Cisplatin Oxaliplatin 5-FU
Colon HT29 4.570.7 160743 0.01570.003 130740 1973 1.0770.16 0.0170.002 25736 0 712 2471
HCT116 3.070.6 2.870.6 0.0570.01 1.270.4 1172 0.1070.02 0.0170.02 9.270.9 2074 5.371.3
HCC2998 3.570.8 110721 0.0170.002 3.770.5 2375 0.7070.14 0.00470.001 25754 71.4 1071
COLO205 5.070.8 872 0.270.1 28781 2 73 1.570.5 0.00670.001 9.572.5 871.6 240720
Breast MCF7 7.071.8 850760 0.0170.002 4300 1673 0.770.1 0.0170.004 32723 5 771 0 71
MDA-MB-435 67714 95713 0.0470.008 38791 9 74 2.070.4 0.0170.002 1372.6 37721 1072
Lung HOP62 6.071.7 7.071.8 0.0170.002 6.372.8 872 0.1470.04 0.0270.04 9.370.9 200740 118732
HOP92 38782 3 76 0.0270.004 1.370.3 2674 0.1070.05 0.00570.001 4.470.4 1.470.2 1171
Ovarian IGROV1 6.571.6 89712 0.0270.004 89721 3874 1.370.3 0.0270.01 2676 107721 2971
OVCAR1 4577 4900 1.270.2 4300 2076 1.070.2 5070.12 12.1073.93 50710 2471
Leukaemia L1210 2076 1.770.3 ND 0.0870.02 ND ND ND ND ND ND
L1210dCK- 2974 10007150 ND 4100 ND ND ND ND ND ND
ND¼not determined.
MDA-MB-435
−10 1 −10 1 −202 −101
−10 1 −20 2 −20 2 −202 −30 3
Log(IC50)−mean log(IC50)
HOP92
HOP62
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−40 4
Sapacitabine CNDAC Seliciclib Doxorubicin Docetaxel
Cisplatin Oxaliplatin Ara-C 5-FU Gemcitabine
Figure 2 Comparative analysis of cytotoxicity of anticancer agents in a panel of human cancer cell lines. The influence of sapacitabine, CNDAC, seliciclib,
doxorubicin, docetaxel, cisplatin, oxaliplatin, ara-C, 5-FU and gemcitabine on the viability of 10 different tumour cell lines was determined using the MTT
assay after continuous drug exposure for four doubling times. The indicated values are calculated as follows: log (IC50 individual cell line)–mean (logIC50).
Negative values indicate that the cell line is more sensitive than the average, where as positive values indicate that the cell line is more resistant than the
average. The horizontal axis represents a log scale.
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ssapacitabine or CNDAC for 48h. Cell cycle analysis showed that 35%
sapacitabine-treated cells arrested in late-S phase and 41% in G2/M
phase. A similar pattern was observed in CNDAC-treated cells with 36
and 36% of cells arrested in late-S and G2/M phases, respectively
(Figure 3). Thus, both agents caused the accumulation of HCT116
cells in G2/M phases as reported previously (Azuma et al, 2001).
Analysis of genes involved in nucleoside analogue
metabolism by quantitative real-time PCR
The transcription profiles of genes known to be involved in the
resistance to nucleoside analogues were analysed in the panel of
cancer cell lines. The mRNA levels of hENT1, dCK, cN-II and POL
genes were analysed using real-time PCR (Figure 4) and calibrated
against HL-60. Colorectal cell lines showed high expression of the
transporter hENT1, low-medium expression of the enzyme dCK
and a variable expression of the cN-II 50-nucleotidase and POL
enzymes. A similar expression profile was observed in breast
cancer cell lines and the HOP92 lung cancer cell line. In contrast,
the HOP62 lung cancer cell line and ovarian cancer cell lines
(OVCAR3 and IGROV1) showed low expression of the transporter
hENT1 and medium expression of cN-II and POL enzymes.
Attempts were made to correlate the antiproliferative effects of
sapacitabine, CNDAC, ara-C and gemcitabine with the level of
mRNA expression of genes encoding the main drug metabolism
proteins. As shown in Figure 5, cells with lower expression of
hENT1 and cells with lower expression of dCK appear to be more
resistant to both CNDAC and ara-C. In contrast, antiproliferative
effects of sapacitabine and gemcitabine were not consistently
associated with mRNA levels of hENT1 and dCK. Furthermore, no
consistent pattern of expression of cN-II and POL genes correlated
with their antiproliferative effects.
Cytotoxicity of sapacitabine in dCK
þ/dCK
  leukaemia
cancer cell lines
The role of dCK in resistance to ara-C has been established with a
correlation observed between dCK deficiency and ara-C resistance
(Galmarini et al, 2002). As dCK is responsible for intracellular
phosphorylation of nucleosides to the active form, we evaluated the
cytotoxicity of sapacitabine against the murine leukaemia cell lines
L1210 and L1210dCK
 , the latter was selected on the basis of
resistance to continued passage in the presence of ara-C. L1210 cells
with dCK activity were sensitive to sapacitabine, CNDAC and ara-C
(IC50 2076, 1.770.3 and 0.0870.02mM, respectively) (Table 1). We
initially confirmed that L1210dCK
  cells were indeed resistant to
ara-C. L1210dCK
  cancer cells were approximately 600- and 2500-fold
more resistant to CNDAC and ara-C, respectively, than L1210 cells
(IC50 10007150 and 4100mM, respectively). However, L1210dCK
 
cells remained sensitive to the parental compound sapacitabine
(IC50 2974mM). Together with mRNA profiling, this suggests that
sapacitabine alone has antitumour effects based on an intracellular
metabolic pathway that may be independent of dCK, which in
some cell lines may differ from that of ara-C and its primary
metabolite CNDAC. This may be due to the action of the palmitoyl
chain of sapacitabine, which is not present in CNDAC.
Combination agent studies
Three schedules were used to study the effect of sequential and
simultaneous exposure of combinations of sapacitabine with other
anticancer agents. In the first schedule, sapacitabine was added to
two cell lines COLO205 and HCT116 for 48h followed by the
addition of oxaliplatin, doxorubicin, docetaxel, gemcitabine or
seliciclib for 24h. The second schedule consisted of inverting the
order of exposure of the cells to the different agents, and the third
schedule was the simultaneous addition of sapacitabine and a
second agent for a period of 48h. Following incubation, the effect
was determined using CIs that represent an affected fraction for
the concentration of drugs corresponding to the IC50 as described
previously (Chou and Talalay, 1984) (Table 2).
In the docetaxel/sapacitabine combinations, synergistic effects
(CIo1) were observed when docetaxel was given before sapaci-
tabine in both cell lines. Antagonistic effects (CI41) were
observed for COLO205 when docetaxel was given after and
concomitantly to sapacitabine. In the HCT116 cell line, an additive
effect was observed for sapacitabine-docetaxel schedule and an
additive/synergistic effect in schedule sapacitabineþdocetaxel
(Table 2). Docetaxel given before sapacitabine appears as more
effective in both cell lines than other schedules.
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Figure 3 Effects of CNDAC and sapacitabine on cell cycle in HCT116 cells detected by flow cytometry. HCT116 cells were harvested after 48h of
incubation with 6mM sapacitabine or CNDAC and analysed for DNA content by FACS analysis. The lower panel represents the distribution of cells in
different phases of cell cycle.
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sIn the gemcitabine/sapacitabine combinations, synergism was
observed in both cell lines with schedule gemcitabine before
sapacitabine, in contrast with the antagonistic effect observed
when the compounds were administered concomitantly or when
sapacitabine was administered before gemcitabine. The synergism
observed between sapacitabine and gemcitabine suggests that,
although closely related, those two compounds may have distinct
mechanisms of action in cancer cells (Table 2). Gemcitabine given
before sapacitabine may be more effective than other schedules.
In the doxorubicin/sapacitabine combinations, synergism was
observed at high concentrations using sequential exposure, while
only additive effects were observed at lower concentrations in both
cell lines. Concomitant schedules yielded additive/antagonistic
effects (Table 2). Sequential exposure seems to be more effective
than combined exposure in both cell lines.
In the oxaliplatin/sapacitabine combinations, various degrees of
synergistic activity (CIo1) were observed irrespective of whether
sapacitabine was administered before or after oxaliplatin in
HCT116. In COLO205 cells, synergy was obtained only when
sapacitabine was given concomitantly with oxaliplatin. Therefore,
in the colon cancer cell line, COLO205, the effect of the
sapacitabine–oxaliplatin combination appeared to be schedule
dependent (Table 2).
Combinations of sapacitabine with seliciclib yielded highly
synergistic effects for all schedules in the human HCT116 colon
cell line, while only additive/antagonistic effects were observed in
COLO205 cells. Overall, the optimal schedule appeared to be when
seliciclib was given before sapacitabine.
DISCUSSION
This study aimed at evaluating the effects of sapacitabine in solid
tumour cell lines. The activity of sapacitabine was investigated in a
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Figure 4 (A) Cytotoxicity of sapacitabine in a panel of 10 cancer cell lines. (B) Profiling mRNA levels of metabolic factors in 10 cell lines. Analysis of main
nucleoside metabolism factors (hENT1, dCK, DNA polymerase and cN-II) was performed by quantitative real-time PCR. RNA was extracted from cells to
determine transcript copy numbers relative to the reference gene 18S. Results were expressed as PCR arbitrary units in all cell lines related to HL-60 cells
PCR arbitrary unit expression.
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spanel of cell lines characterised for resistance to anticancer agents,
considered as representative of the most commonly observed
tumour types. Cytotoxics evaluated in this study were selected
based on their mechanisms of action, including nucleoside
analogues for evaluation of cross-resistance with ara-C, gemcita-
bine and CNDAC, as well as based on more pragmatic reasons
aiming at comparing cytotoxic effects of sapacitabine with that of
already used anticancer agents. Finally, this study aimed at
identifying a pharmacological rational for combining sapacitabine
with other anticancer agents in further clinical studies including
seliciclib, a novel cell cycle inhibitor currently in clinical trials. In
our study, it is surely not surprising that sapacitabine and CNDAC
may display overlapping cytotoxic effects if the later is a metabolite
of the former. However, differences observed between those two
compounds may suggest that sapacitabine may act both through
its bioconversion into CNDAC and may also act by other
mechanisms. Although of major interest, it remains to be
demonstrated whether sapacitabine requires to be converted by
amidases in vitro or can be directly incorporated into cancer cells,
undergoing specific metabolic processes. We observed that
sapacitabine displayed antiproliferative activity across a broad
range of concentrations in a variety of human cancer cell lines,
including cancer cells that were shown to be primarily resistant to
several anticancer drugs. Moreover, sapacitabine showed cytotoxic
activity against dCK-deficient L1210 cells, indicating a dCK-
independent mechanism of action. Finally, sapacitabine showed a
synergistic effect when combined with gemcitabine and sequence-
specific synergy with doxorubicin and oxaliplatin. Based on these
observations, sapacitabine appeared as a good candidate for
further evaluation in combination with currently used clinical
anticancer agents in tumour types with unmet needs.
The antiproliferative effects of sapacitabine in terms of IC50
values were better than those observed with CNDAC and ara-C.
When comparing the cytotoxic effects of these three pyrimidine
analogues, sapacitabine appears to retain activity in several cells
that were poorly sensitive to CNDAC and ara-C such as colon
HT29 and HCC2998, breast MCF7 and ovarian IGROV1. In
contrast, gemcitabine achieved cell growth inhibition at lower
concentrations. Our study, as well as previously published data,
seems to indicate that both CNDAC and sapacitabine are less
potent than gemcitabine in cellular and in vivo assays. However
this may not turn out to be detrimental in the clinic given that
sapacitabine may be given orally and displays additive/synergistic
effects with other anticancer agents, allowing maintaining activity
in clinical trials. We observed that active concentrations, as
assessed by IC50 values, ranged from 3.0 to 67.0mM with colon
HCT116 and breast MDA-MB-435 being the most sensitive and
resistance cancer cells respectively. Based on animal data and
preliminary pharmacokinetic information, this range of concen-
trations appears to be achievable in future clinical trials in
humans. Other authors have demonstrated that sapacitabine also
had cytotoxic activity against a broad spectrum of human tumour
cells, and although the average cytotoxicities were comparable with
CNDAC, sapacitabine was more potent (Hanaoka et al, 1999). In
gastric, lung, mammary, colon, ovary and epidermoid cell lines,
the IC50 values for sapacitabine ranged from 0.1 to 11mM, whereas
for CNDAC they ranged from 0.1 to 4350mM (Azuma et al, 1993;
Hanaoka et al, 1999; Matsuda and Sasaki, 2004).
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Figure 5 Correlation between mRNA levels and sensitivity to deoxycytidine analogues. Expression levels of hENT1, dCK, cN-II and DNA-pol mRNAs
were correlated with cytotoxicity of sapacitabine, CNDAC, ara C and gemcitabine, as measured by IC50 values, in 10 tumour cell lines. All values from the
reverse transcription-PCR are standardised with respect to HL60. The R
2 value corresponds with the correlation coefficient calculated by linear regression
analysis. R
2o0.1 was not displayed.
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sFurthermore, sensitivity profiles of dCK-proficient and -deficient
cell lines demonstrated resistance to ara-C and CNDAC when dCK is
downexpressed. L1210-dCK
  cells were approximately 2500- and
600-fold more resistant to ara-C and CNDAC than parental L1210-
dCK
þ cells, respectively. This resistance was not found when cells
were incubated with sapacitabine, suggesting a transport-related
mechanism of resistance. This finding showing that sapacitabine
retained cytotoxic activity against dCK-deficient L1210 cells strongly
suggests that sensitivity to sapacitabine may not only be dependent
on dCK expression. The role of dCK in sensitivity to CNDAC and
sapacitabine has also been observed in MES-SA-10K, a cell line that
derives from MES-SA cell deficient in dCK, selected after repeated
passages in the presence of gemcitabine (Galmarini and Green,
unpublished observations; Jordheim et al, 2004). Although dCK-
independent mechanisms are not yet finally understood, other
enzymes such as CDA have been recently shown to play a role in the
mechanism of action of sapacitabine (Fleming et al, 2007). These
results support the idea that sapacitabine may emerge as a potent
and active agent against dCK-deficient cells.
In our experiments, exposure of HCT116 cancer cells to
sapacitabine and CNDAC for 48h led to the accumulation of cells
in G2 phase of cell cycle. The G2 checkpoint is regarded as a
resistance mechanism that could permit cells to repair potentially
lethal damage such as single-strand breaks. Abrogating this
checkpoint reduces the possibility of repair and hence leads to
increased cell death. Our data are consistent with the hypothesis
that cells treated by sapacitabine or CNDAC may directly progress
into G2/M phase of cell cycle. Other authors indicated that after
incubation with cytostatic concentrations of CNDAC, cell cycle
progression was delayed during S phase, but that cells arrested
predominantly in the G2 phase (Azuma et al, 2001; Liu et al, 2005).
This unique cell cycle arrest pattern was related to the strand-
breaking action of CNDAC caused by the b-elimination-mediated
mechanism. The cytotoxic action of CNDAC may be explained by
the fact that human tumour cells are able to accumulate and retain
CNDACTP and that the analogue has the ability to terminate
further extension.
To further understand the basis of sapacitabine and CNDAC
activity in these cell lines of differing origin, we measured mRNA
levels of several enzymes commonly implicated in resistance to
nucleoside analogues such as dCK, cN-II, POL and hENT1.
Colorectal, breast and the HOP92 lung cancer cell lines commonly
demonstrated high expression levels of hENT1, low-medium levels
of dCK and variable expression of both cN-II and DNA
polymerase, and HOP62 lung and ovarian cancer cell lines showed
low expression of the transporter hENT1 and medium cN-II and
DNA polymerase expression; however, no obvious correlation
between drug sensitivity and mRNA expression levels of these
metabolic factors was identified. Our results are in contrast to
those described by Matsuda and Sasaki (2004). These authors
demonstrated that levels of expression of metabolic enzymes such
as dCK or cytidine deaminase influenced the antiproliferative
effects of CNDAC. Moreover, expression and/or function of these
factors appear to be influenced by the activation of various
oncogenes (Zhang et al, 1999).
To further improve the effects of sapacitabine, circumvent
potential resistance to this agent, and find combinations that may
be used in clinical trials, we investigated a number of sapacitabine
combinations using both simultaneous and sequential exposures
to drugs. Combination studies demonstrated synergistic effects
when sapacitabine was combined with compounds such as
oxaliplatin, gemcitabine, docetaxel and doxorubicin over a broad
range of concentrations in human colon cancer cells using several
administration schedules. Interestingly, synergy might be se-
quence-dependent for oxaliplatin and docetaxel. Synergism
between sapacitabine and gemcitabine strongly suggests that
although closely related these two compounds have distinct
mechanisms of action in cancer cells. Phase I clinical data have
shown that after oral administration, sapacitabine was not
detectable in urine suggesting that most of sapacitabine is
converted into CNDAC in human (Delaunoit et al, 2006). In our
experiments, sapacitabine was consistently more cytotoxic than
CNDAC leading to combination studies using sapacitabine instead
of CNDAC. Although combination with CNDAC was not
Table 2 Summary of effects of combination agent study using five anticancer agents in combination with sapacitabine in three treatment schedules
CI, mean (SD)
COLO205 HCT116
Combination schedule ED o0.25
ED 0.25–
0.50
ED 0.50–
0.75 ED 40.75 ED o0.25
ED 0.25–
0.50
ED 0.50–
0.75 ED 40.75
Docetaxel-based 48h Sapa-24h Doc — — 1.8 (1.2) 1.0 (0.6) 7.4 (5.0) 0.9 (0.1) 0.9 (0.4) 1.3 (0.5)
combinations 24h Doc-48h Sapa — 0.5 (0.1) 1.2 (0.1) 0.5 (0.3) 2.1 (1.1) 0.7 (0.1) 0.8 (0.1) 0.1 (0.1)
48h Sapa+Doc 1.3 (0.1) 1.5 (0.7) 0.9 (0.2) 0.5 (0.1) — 1.5 (0.1) 0.7 (0.3) 0.7 (0.4)
Gemcitabine-based 48h Sapa-24h Gem 1.4 (0.5) 1.0 (0.1) 1.0 (0.4) 1.2 (0.8) 2.6 (0.9) — 0.7 (0.1) 1.3 (0.8)
combinations 24h Gem-48h Sapa 1.5 (0.3) 1.0 (0.3) 0.5 (0.1) 0.4 (0.2) — 0.4 (0.1) 0.5 (0.3) 0.4 (0.3)
48h Sapa+Gem 6.0 (2.0) 1.7 (0.8) 1.0 (0.3) 0.6 (0.5) — — 1.3 (0.9) 0.4 (0.2)
Doxorubicin-based 48h Sapa-24h Dox — — — 0.6 (0.5) — 1.1 (0.2) 0.8 (0.4) 0.7 (0.5)
combinations 24h Dox-48h Sapa — — — 0.7 (1.1) 0.8 (0.1) 0.8 (0.3) 1.1 (0.5) 0.6 (0.6)
48h Sapa+Dox — 2.0 (1.9) 1.2 (0.9) 0.7 (0.7) 1.9 (0.9) 1.0 (0.3) 1.2 (0.2) 1.0 (0.3)
Oxaliplatin-based 48h Sapa-24h Oxa — — — 1.5 (0.8) 8.0 (1.2) 0.4 (0.1) 0.3 (0.1) 0.6 (0.4)
combinations 24h Oxa-48h Sapa — 1.7 (0.9) 1.4 (1.2) 0.6 (0.4) 1.8 (0.6) 0.5 (0.4) 0.5 (0.4) 0.4 (0.4)
48h Sapa+Oxa — 1.2 (0.7) 1.0 (0.3) 0.2 (0.1) 2.4 (1.0) 1.1 (0.2) 0.7 (0.2) 0.7 (0.7)
Seliciclib-based 48h Sapa-24h Sel — 2.2 (1.1) 1.8 (0.5) 1.3 (0.5) — — 1.4 (1.2) 0.5 (0.3)
combinations 24h Sel-48h Sapa 1.2 (0.3) 1.4 (0.1) 0.9 (0.2) 0.6 (0.1) — 0.8 (0.2) 0.7 (0.1) 0.7 (0.5)
48h Sapa+Sel — — 0.7 (0.6) 0.8 (0.4) — 1.0 (0.1) 0.8 (0.3) 0.7 (0.3)
CI¼combination indices ; Doc¼docetaxel; Dox¼doxorubicin; ED¼fraction of cells affected by drug combination; Gem¼gemcitabine; Oxa¼oxaliplatin; Sapa¼sapacitabine;
Sel¼seliciclib.
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sperformed, it is unlikely that results may have been superior with
CNDAC than that of sapacitabine in our models.
In summary, our study provides additional data supporting
further preclinical and clinical pharmacological investigations
of sapacitabine in human cancers. Our results suggest that
sapacitabine possesses an interesting toxicity profile compared to
several other anticancer agents including other pyrimidine analo-
gues. Moreover, sapacitabine showed cytotoxic activity against
dCK-deficient cell lines indicating that this compound can be active
in cells resistant to CNDAC, ara-C and other nucleoside analogues.
Our preclinical data showed that sapacitabine combinations yield
synergistic activity with other anticancer agent (including gemcita-
bine) supporting further evaluation of those combinations both
simultaneously and sequentially in clinical trials.
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